Multiple modes of action for antibodies targeting GARP-expressing cells in tumors

Cancer immunotherapies, such as monoclonal antibodies (mAbs) directed against PD-1, aim at boosting immune responses against tumor cells. They have become a standard of care for several types of cancer. However, a majority of patients do not respond to current immunotherapies. Resistance to PD-1 blockade can in part be explained by the action of TGF-b1, an immunosuppressive cytokine activated notably by regulatory T cells (Tregs) via a mechanism that requires protein GARP. We developed antibodies against GARP:TGF-b1 complexes that block TGF-b1 activation by Tregs and we evaluated their anti-tumor efficacy in tumor-bearing mice. We observed that anti-GARP:TGF-b1 mAbs induce the regression of tumors otherwise resistant to anti-PD-1, and we showed that combined blockade of GARP:TGF-b1 and PD-1 can exert anti-tumor activity via multiple modes of action. This may prove important for the selection of cancer patients who could benefit from this novel form of immunotherapy in the clinics.
(BIFA - Sciences biomédicales et pharmaceutiques) -- UCL, 2021